1. Home
  2. OSPN vs FULC Comparison

OSPN vs FULC Comparison

Compare OSPN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OneSpan Inc.

OSPN

OneSpan Inc.

HOLD

Current Price

$12.77

Market Cap

576.4M

Sector

Technology

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$12.01

Market Cap

468.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OSPN
FULC
Founded
1991
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
576.4M
468.1M
IPO Year
1998
2019

Fundamental Metrics

Financial Performance
Metric
OSPN
FULC
Price
$12.77
$12.01
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$17.00
$16.38
AVG Volume (30 Days)
636.3K
2.6M
Earning Date
10-30-2025
10-29-2025
Dividend Yield
3.75%
N/A
EPS Growth
99.92
N/A
EPS
1.49
N/A
Revenue
$241,436,000.00
N/A
Revenue This Year
$0.69
N/A
Revenue Next Year
$1.96
N/A
P/E Ratio
$8.58
N/A
Revenue Growth
N/A
2752.05
52 Week Low
$11.00
$2.32
52 Week High
$20.37
$15.74

Technical Indicators

Market Signals
Indicator
OSPN
FULC
Relative Strength Index (RSI) 49.66 53.87
Support Level $12.62 $11.71
Resistance Level $12.96 $12.90
Average True Range (ATR) 0.41 1.16
MACD 0.07 -0.12
Stochastic Oscillator 45.14 47.54

Price Performance

Historical Comparison
OSPN
FULC

About OSPN OneSpan Inc.

OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Share on Social Networks: